Moderna (NASDAQ:MRNA) Shares Gap Down - Time to Sell?

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $39.77, but opened at $38.55. Moderna shares last traded at $38.25, with a volume of 4,196,039 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Hsbc Global Res upgraded shares of Moderna from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 28th. Barclays dropped their price target on Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a report on Friday, November 8th. Jefferies Financial Group reduced their price objective on Moderna from $65.00 to $55.00 and set a "hold" rating for the company in a research note on Tuesday, October 15th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a "sell" rating to a "hold" rating and lowered their target price for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, Bank of America reduced their price target on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating for the company in a research report on Friday, September 13th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $90.22.

Moderna Trading Down 7.3 %

The stock's fifty day moving average price is $59.28 and its 200 day moving average price is $97.40. The stock has a market cap of $14.18 billion, a P/E ratio of -6.33 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the prior year, the company earned ($1.39) earnings per share. The business's revenue was up 3.8% compared to the same quarter last year. Equities research analysts expect that Moderna, Inc. will post -9.43 earnings per share for the current year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 2,930 shares of company stock worth $217,170. Corporate insiders own 15.70% of the company's stock.

Institutional Investors Weigh In On Moderna

A number of large investors have recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna during the second quarter worth about $26,000. Family Firm Inc. purchased a new position in shares of Moderna in the second quarter worth $33,000. Cedar Wealth Management LLC boosted its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Bank & Trust Co purchased a new position in Moderna during the second quarter valued at $36,000. Finally, Hanseatic Management Services Inc. bought a new stake in Moderna in the 2nd quarter valued at $48,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.